iSign Solutions (ISGN) 10-Q 15 May 14 2014 FY Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	3 Months Ended
	Mar. 31, 2014	15-May-14	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'Communication Intelligence Corp	'	'
Entity Central Index Key	'0000727634	'	'
Document Type	'10-Q	'	'
Document Period End Date	31-Mar-14	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
EntityVoluntaryFilers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	232,559,488	'
Entity Public Float	'	'	$6,958,686

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'	'
Cash and cash equivalents	$1,147	$945	$486
Accounts receivable, net of allowance of $17 at March 31, 2014 and $22 at December 31, 2013	278	410	'
Prepaid expenses and other current assets	58	57	'
Total current assets	1,483	1,412	'
Property and equipment, net	18	17	'
Patents, net	1,201	1,290	'
Other assets	29	29	'
Total assets	2,731	2,748	'
Current liabilities:	'	'	'
Accounts payable	185	327	'
Accrued compensation	311	315	'
Other accrued liabilities	240	232	'
Deferred revenue	512	490	'
Total current liabilities	1,248	1,364	'
Deferred revenue long-term	19	74	'
Deferred rent	75	86	'
Derivative liability	20	25	'
Total liabilities	1,362	1,549	'
Commitments and Contingencies	'	'	'
Stockholders' deficit	'	'	'
Common Stock, $0.01 par value; 1,500,000 shares authorized; 232,559 issued and outstanding at March 31, 2014 December 31, 2013	2,390	2,390	'
Treasury shares, 6,500 shares at March 31, 2014 and December 31, 2013 respectively	-325	-325	'
Additional paid in capital	96,399	96,172	'
Accumulated deficit	-120,245	-119,184	'
Accumulated other comprehensive loss	-14	-14	'
Total CIC stockholder's equity (deficit)	1,905	1,735	'
Non-Controlling interest	-536	-536	'
Total stockholders' equity (deficit)	1,369	1,199	-357
Total liabilities and shareholders' equity	2,731	2,748	'
Series A-1 Preferred Stock [Member]	'	'	'
Stockholders' deficit	'	'	'
Preferred stock by class of stock	1,052	1,031	880
Total stockholders' equity (deficit)	1,052	1,031	880
Series B Preferred Stock [Member]	'	'	'
Stockholders' deficit	'	'	'
Preferred stock by class of stock	9,506	9,232	7,380
Total stockholders' equity (deficit)	9,506	9,232	7,380
Series C Preferred Stock [Member]	'	'	'
Stockholders' deficit	'	'	'
Preferred stock by class of stock	5,197	5,086	3,569
Total stockholders' equity (deficit)	5,197	5,085	3,569
Series D-1 Preferred Stock [Member]	'	'	'
Stockholders' deficit	'	'	'
Preferred stock by class of stock	3,693	3,345	'
Total stockholders' equity (deficit)	3,693	3,345	'
Series D-2 Preferred Stock [Member]	'	'	'
Stockholders' deficit	'	'	'
Preferred stock by class of stock	4,252	4,002	'
Total stockholders' equity (deficit)	$4,252	$4,002	'

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Accounts receivable, allowance	$17,000	$22,000
Stockholders' deficit	'	'
Common Stock, par value	$0.01	$0.01
Common Stock, shares authorized	1,500,000,000	1,500,000,000
Common Stock, shares issued	232,560,000	232,560,000
Common Stock, shares outstanding	232,560,000	232,560,000
Treasury shares	6,500,000	6,500,000
Series A-1 Preferred Stock [Member]	'	'
Stockholders' deficit	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	1,052,000	1,031,000
Preferred stock, shares outstanding	1,052,000	1,031,000
Preferred stock, liquidation preference	1,052,000	'
Series B Preferred Stock [Member]	'	'
Stockholders' deficit	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	14,000,000	14,000,000
Preferred stock, shares issued	11,377,000	11,102,000
Preferred stock, shares outstanding	11,377,000	11,102,000
Preferred stock, liquidation preference	17,066,000	'
Series C Preferred Stock [Member]	'	'
Stockholders' deficit	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	9,000,000	9,000,000
Preferred stock, shares issued	4,619,000	4,508,000
Preferred stock, shares outstanding	4,619,000	4,508,000
Preferred stock, liquidation preference	6,929,000	'
Series D-1 Preferred Stock [Member]	'	'
Stockholders' deficit	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	4,302,000	3,415,000
Preferred stock, shares outstanding	4,302,000	3,415,000
Preferred stock, liquidation preference	4,302,000	'
Series D-2 Preferred Stock [Member]	'	'
Stockholders' deficit	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	9,000,000	9,000,000
Preferred stock, shares issued	5,303,000	4,783,000
Preferred stock, shares outstanding	5,303,000	4,783,000
Preferred stock, liquidation preference	$5,303,000	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue:	'	'
Product	$128	$71
Maintenance	173	164
Total revenues	301	235
Cost of sales:	'	'
Product	4	5
Maintenance	54	73
Research and development	540	512
Sales and marketing expense	308	309
General and administrative expense	463	596
Total operating costs and expenses	1,369	1,495
Loss from operations	-1,068	-1,260
Other expense, net	2	-1
Gain (loss) on derivative liability	5	64
Net loss	-1,061	-1,197
Accretion of beneficial conversion feature, preferred shares:	'	'
Related party	-73	-33
Other	-301	-22
Preferred stock dividends:	'	'
Related party	-328	-262
Other	-293	-216
Income tax	'	'
Net loss before non-controlling interest	-2,056	-1,730
Net loss attributable to non-controlling interest	'	'
Net loss attributable to common stockholders	($2,056)	($1,730)
Basic and diluted loss per common share	($0.01)	($0.01)
Weighted average common shares outstanding, basic and diluted	232,560	225,875

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($1,061)	($1,197)
Adjustments to reconcile net loss to net cash used for operating activities:	'	'
Depreciation and amortization	92	96
Stock-based employee compensation	92	254
(Gain) loss on derivative liability	-5	-64
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	132	591
Prepaid expenses and other assets	-1	9
Accounts payable	-142	74
Accrued Compensation	-4	-41
Other accrued liabilities	-3	'
Deferred revenue	-33	-38
Net cash used in operating activities	-933	-316
Cash flows from investing activities:	'	'
Acquisition of property and equipment	-4	-2
Net cash used in investing activities	-4	-2
Cash flows from financing activities:	'	'
Proceeds from exercise of warrants for cash	'	29
Net cash provided by financing activities	1,139	29
Effect of exchange rate changes on cash and cash equivalents	'	'
Net decrease in cash and cash equivalents	202	-289
Cash and cash equivalents at beginning of period	945	486
Cash and cash equivalents at end of period	1,147	197
Supplemental disclosure of cash flow information:	'	'
Interest paid	'	'
Income tax paid	'	'
Non-cash financing and investing transactions:	'	'
Dividends on preferred shares	621	478
Accretion of beneficial conversion feature on issuance of convertible Preferred Stock	306	'
Accretion of beneficial conversion feature on issuance of Preferred Stock dividends	$68	$55

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Comprehensive income:	'	'
Net loss	($1,061)	($1,197)
Foreign currency translation adjustment	'	14
Total comprehensive loss	($1,061)	($1,183)

Nature_of_business_basis_of_pr

Nature of business, basis of presentation and summary of significant accounting policies	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of business, basis of presentation and summary of significant accounting policies	'
	1. Nature of business and summary of significant accounting policies
	Basis of Presentation
	The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2013.
	The accompanying unaudited condensed consolidated financial statements of Communication Intelligence Corporation and its subsidiary (the "Company" or "CIC") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year.
	The Company is a leading supplier of electronic signature products and the recognized leader in biometric signature verification. CIC enables companies to achieve truly paperless workflow in their electronic business processes by providing multiple signature technologies across virtually all applications. CIC's solutions are available both in software-as-a-service ("SaaS") and on-premise delivery models and afford "straight-through-processing," which can increase customer revenue by enhancing user experience and can also reduce costs through paperless and virtually error-free electronic transactions that can be completed significantly quicker than paper-based procedures. To date, the Company primarily has delivered biometric and electronic signature solutions to channel partners and end-user customers in the financial services industry.
	The Company's research and development activities have given rise to numerous technologies and products. The Company's core technologies can be referred to as "transaction-enabling" technologies. These technologies include various forms of electronic signatures, such as handwritten biometric, click-to-sign and others, as well signature verification, cryptography and the logging of audit trails to show signers' intent. These technologies can enable secure, legal and regulatory compliant electronic transactions that can enhance customer experience at a fraction of the time and cost required by traditional, paper-based processes. The Company's products include SignatureOne® Ceremony® Server, the iSign® suite of products and services, including iSign® Enterprise and iSign® Console™, Sign-it® and the iSign® toolkits.
	Going Concern
	The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Except for 2004, the Company has incurred significant losses since its inception and, at March 31, 2014, the Company's accumulated deficit was approximately $120,245. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2014, the Company's cash balance was approximately $1,147. These factors raise substantial doubt about the Company's ability to continue as a going concern.
	There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Reclassifications
	Certain prior year amounts have been reclassified between Series C Preferred Stock, Series D-1 Preferred Stock, Series D-2 Preferred Stock and Additional paid in capital on the accompanying condensed consolidated balance sheet to properly reflect accretion of the beneficial conversion feature on certain issuances of the Company's Preferred Stock. These reclassifications do not impact the condensed consolidated statement of operations or the condensed consolidated statement of cash flows.
	Accounting Changes and Recent Accounting Pronouncements
	Accounting Standards Issued But Not Yet Adopted
	Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company's financial position, results of operations and cash flows.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	2. Concentrations
	The following table summarizes accounts receivable and revenue concentrations:
		Accounts Receivable		Total Revenue
		As of March 31,		for the three months
				ended March 31,
		2014	2013	2014	2013
	Customer #1	32%	37%	12%
	Customer #2	26%
	Customer #3	18%		22%
	Customer #4		18%
	Customer #5		18%
	Customer #6			12%	15%
	Customer #7				15%
	Total concentration	76%	73%	46%	30%

Patents

Patents	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Patents	'
	3. Patents
	The Company performs intangible asset impairment analysis at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets.
	Management completed an analysis of the Company's patents as of December 31, 2013. Based on that analysis, the Company concluded that no impairment of the carrying value of the patents existed. The Company believes that no events or circumstances changed during the three months ended March 31, 2014 that would impact this conclusion.
	Amortization of patent costs was $89 for the three months ended March 31, 2014 and $92 for the three months ended March 31, 2013, respectively.
	Intangible Assets
	The following table summarizes intangible assets:
	Amortizable intangible assets:	31-Mar-14		31-Dec-13
		Carrying	Accumulated	Carrying	Accumulated
		Amount	Amortization	Amount	Amortization
	Patents	$	$	$	$
		6,745	-5,544	6,745	-5,455

Derivative_Liability

Derivative Liability	3 Months Ended
	Mar. 31, 2014
Derivative liability [Abstract]	'
Derivative liability	'
	4. Derivative liability
	The Company has determined that a contract that would otherwise meet the definition of a derivative but is both (a) indexed to the Company's own stock and (b) classified in stockholders' equity in the statement of financial position would not be considered a derivative financial instrument. The Company applies a two-step model in determining whether a financial instrument or an embedded feature is indexed to an issuer's own stock and thus able to qualify for the scope exception.
	The Company issued certain warrants in connection with financing transactions from 2010 through 2012 that require liability classification because of certain provisions that may have resulted in an adjustment to the number of shares issued upon settlement and an adjustment to their exercise price. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company used a simulated probability valuation model to value these warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically, probabilities) used may cause the value to be higher or lower than that reported. The assumptions used in the model required significant judgment by management and include the following: volatility, expected term, risk-free interest rate, dividends, warrant holders' expected rate of return, reset provisions based on expected future financings, projected stock prices, and probability of exercise. The estimated volatility of the Company's common stock at the date of issuance, and at each subsequent reporting period, is based on historical volatility. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Dividends are estimated at 0% based on the Company's history of no common stock dividends.
	The fair value of the outstanding derivative liabilities at March 31, 2014, and December 31, 2013, was $20 and $25, respectively.
	Fair value measurements:
	Assets and liabilities measured at fair value as of March 31, 2014, are as follows:
		Value at	Quoted	Significant	Significant
			prices in	other	unobservable
			active	observable	inputs
			markets	inputs
			(Level 1)	(Level 2)	(Level 3)
		31-Mar-14
	Derivative liability	$	$	$	$
		20	-	-	20
		31-Dec-13
	Derivative liability	$	$	$	$
		25	-	-	25
	The fair value framework requires a categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets and liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:
	Level 1: Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
	Level 2: Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
	Level 3: Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
	The Company's assets and liabilities measured at fair value, whether recurring or non-recurring, at March 31, 2014, and December 31, 2013, and the fair value calculation input hierarchy level that we have determined applies to each asset and liability category.
	Changes in the fair market value of the Level 3 derivative liability for the three month period ended March 31, 2014 are as follows:
		Derivative Liability
	Balance at January 1, 2014	$
		25
	Gain on derivative liability	-5
	Balance at March 31, 2014	$
		20

Net_loss_per_share

Net loss per share	3 Months Ended
	Mar. 31, 2014
Net loss per share [Abstract]	'
Net loss per share	'
	5. Net loss per share
	The Company calculates basic net loss per share, based on the weighted average number of shares outstanding, and when applicable, diluted income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding.
	The following table lists shares and warrants that were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants and the conversion of such preferred shares would be anti-dilutive:
		For the three Months Ended
		31-Mar-14	31-Mar-13
	Stock options	72,038	70,270
	Warrants	94,240	149,022
	Preferred shares as if converted
	Series A-1Preferred Stock	7,513	6,941
	Series B Preferred Stock	17,065	237,866
	Series C Preferred Stock	205,294	190,146
	Series D-1 Preferred Stock	191,189	51,193
	Series D-2 Preferred Stock	106,069	67,682
	The following table is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted EPS calculations and sets forth potential shares of Common Stock that are not included in the diluted net loss per share calculation as the effect is antidilutive:
		Three Months Ended
		March 31,	March 31,
		2014	2013
	Numerator-basic and diluted net loss	$	$
		-2,056	-1,730
	Denominator-basic or diluted weighted average number of common shares outstanding	232,560	225,875
	Net loss per share - basic and diluted	$	$
		-0.01	-0.01

Equity

Equity	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	6. Equity
	Share-based compensation expense is based on the estimated grant date fair value of the portion of share-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black Scholes valuation model.
	Forfeitures of share-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended March 31, 2014 and 2013, was approximately 9.76% and 9.73%, respectively, based on historical data.
	Valuation and Expense Information:
	The weighted-average fair value of stock-based compensation is based on the Black Scholes valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized over the vesting period of the options. The fair value calculations are based on the following assumptions:
		Three Months Ended	Three Months Ended
		31-Mar-14	31-Mar-13
	Risk free interest rate	0.04% - 4.92%	0.62% - 5.11%
	Expected term (years)	3.33 - 6.21	2.82 - 7.00
	Expected volatility	91.99% - 198.38%	93.63% - 147.41%
	Expected dividends	None	None
	The Company granted 2,500 stock options during the three months ended March 31, 2014, at a weighted average exercise price of $0.027 per share. No stock options were exercised during the three month period ended March 31, 2014.
	The Company granted 26,241 stock options during the three months ended March 31, 2013, at a weighted average exercise price of $0.04 per share. No stock options were exercised during the month period ended March 31, 2013.
	The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three months ended March 31:
		2014	2013
	Research and development	$	$
		27	68
	Sales and marketing	12	25
	General and administrative	48	146
	Director	5	15
	Total Stock-based compensation	$	$
		92	254
	A summary of option activity under the Company's plans as of March 31, 2014 and 2013 is as follows:
	Options	2014				2013
		Shares	Weighted	Weighted	Aggregate	Shares	Weighted	Weighted	Aggregate
			Average	Average	Intrinsic		Average	Average	Intrinsic
			Exercise	Remaining	Value		Exercise	Remaining	Value
			Price	Contractual			Price	Contractual
				Term				Term
	Outstanding at January 1,	69,537	$		$	44,529	$		$
			0.05		-		0.05		2,230
	Granted	2,500	$		$	26,241	$		$
			0.03		7		0.04		1,179
	Exercised	-	$		$	-	$		$
			-		-		-		-
	Forfeited or expired	-	$		$	-500	$		$
			-		-		0.09		43
	Outstanding at March 31	72,037	$	4.85	$	70,270	$	5.75	$
			0.05		7		0.05		3,367
	Vested and expected to vest at March 31	65,007	$	4.41	$	70,270	$	5.05	$
			0.05		7		0.05		3,367
	Exercisable at March 31	48,445	$	5.05	$	27,036	$	5.05	$
			0.05		-		0.05		1,043
	The following tables summarize significant ranges of outstanding and exercisable options as of March 31, 2014:
	Range of Exercise Prices	Options Outstanding			Options Exercisable
		Number	Weighted	Weighted	Number	Weighted
		Outstanding	Average	Average	Outstanding	Average
			Remaining	Exercise		Exercise
			Contractual	Price		Price
			Term (in years)
	$ 0.07 - $0.50	72,037	4.85	$	48,445	$
				0.05		0.05
	A summary of the status of the Company's non-vested shares as of March 31, 2014, is as follows:
	Non-vested Shares	Shares	Weighted
			Average
			Grant-Date
			Fair Value
	Non-vested at January 1, 2014	26,158	$
			0.04
	Granted	2,500	$
			0.03
	Exercised	-	$
			-
Forfeited	-	$
		-
Vested	-5,066	$
		0.04
Non-vested at March 31, 2014	23,592	$
		0.04
As of March 31, 2014, there was $292 of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 1.1 years.
Preferred Stock
Information with respect to the class of Preferred Stock as of March 31, 2014 is as follows:
Class of	Issue Date	Annual	Annual	Liquidation	Conversion	Total	Common
Preferred		Dividend	Dividend	Preference	Price	Preferred	Shares to be
Stock			Payable, in			Shares	issued if
			Cash or In			Outstanding	Fully
			Kind				Converted
Series A-1	May-08	8%	Quarterly in Arrears	$	$	1,052	7,514
				1	0.14
Series B	Aug-10	10%	Quarterly in Arrears	$	$	11,377	262,559
				1.5	0.0433
Series C	December/March 2011	10%	Quarterly in Arrears	$	$	4,619	205,294
				1.5	0.0225
Series D-1	November 2012/May and December 2013/February and March 2014	10%	Quarterly in Arrears	$	$	4,302	191,189
				1	0.0225
Series D-2	November 2012/May and December 2013/February and March 2014	10%	Quarterly in Arrears	$	$	5,303	106,068
				1	0.05
Information with respect to dividends issued on the Company's Preferred stock for the period ended March 31, is as follows:
	March 31,		March 31,
	2014	2013	2014	2013
	Dividends		Beneficial Conversion Feature
			Related to dividends
Series A-1	$	$	$	$
	20	19	-	-
Series B	274	248	-	-
Series C	111	103	37	43
Series D-1	93	28	31	12
Series D-2	123	81	-	-
Total	$	$	$	$
	621	478	68	55
Series A-1 Preferred Stock
The shares of Series A-1 Preferred Stock are convertible any time and are subordinate to the Series B, Series C and Series D Preferred Stock.
Series B Preferred Stock
The shares of Series B Preferred Stock are convertible at any time and are subordinate to the Series C and Series D Preferred Stock.
Series C Preferred Stock
The shares of Series C Preferred Stock are convertible into Common Stock at any time and are subordinate to the Series D Preferred Stock.
Series D Preferred Stock
The material terms of the Series D-1 and Series D-2 Preferred Stock, other than the initial conversion price, are essentially the same. The shares of Series D Preferred Stock are convertible at any time and rank senior to the Company's outstanding shares of Series A-1, Series B and Series C Preferred Stock, and of Common Stock with respect to dividend rights and liquidation preferences.
In May 2013, the Company completed a private placement of 230 units of Series D Preferred Stock consisting of one (1) share of Series D-1 Preferred Stock and four (4) shares of Series D-2 Preferred Stock. The private placement provided $1,150 in proceeds to the Company.
On December 31, 2013, the Company converted approximately $1,179 of short-term debt plus accrued interest into 786 shares of Series D-1 Preferred Stock and 393 shares of Series D-2 Preferred Stock. The investors can receive up to one hundred percent (100%) warrant coverage. These warrants are immediately exercisable and expire three (3) years from the date of issuance. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision.
On December 31, 2013, the Company sold for $870 in cash, net of $40 administrative fee paid to SG Phoenix, 607 Shares of Series D-1 preferred Stock and 303 shares of Series D-2 Preferred Stock. The investors can receive up to one hundred percent (100%) warrant coverage. These warrants are immediately exercisable and expire three (3) years from the date of issuance. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision.
In connection with the December 31, 2013, offering, the Company adjusted the number of shares of Series D-1 Preferred Stock and Series D-2 Preferred Stock issued to investors in the May 2013 offering described above, in order to give such investors shares of Series D-1 Preferred Stock and Series D-2 Preferred Stock in the same ratio as offered to Investors in the December 31, 2013, offering. This resulted in an exchange of 537 shares of Series D-2 Preferred into Series D-1 Preferred. The Company also issued warrants to purchase Common Stock in the same manner as offered to investors in the December 31, 2013, offering.
On February 7, 2014, the Company sold for $733 in cash, net of $47 administrative fee paid in cash to SG Phoenix and a nonrelated third party, 520 Shares of Series D-1 preferred Stock and 260 shares of Series D-2 Preferred Stock. The investors can receive up to one hundred percent (100%) warrant coverage. These warrants are immediately exercisable and expire December 31, 2016. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision.
On March 6, 2014, the Company sold for $406 in cash, net of $4 in administrative fees paid in cash to an unrelated third party, 273 Shares of Series D-1 preferred Stock and 137 shares of Series D-2 Preferred Stock. The investors can receive up to one hundred percent (100%) warrant coverage. These warrants are immediately exercisable and expire December 31, 2016. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision.
SG Phoenix received warrants to purchase 3,000 shares of Common stock, and two unrelated parties received warrants to purchase an aggregate of 1,600 shares of Common Stock in payment of administrative and finder's fees associated with the financings, in addition to the cash payments discussed above. These warrants are immediately exercisable and expire three (3) years from the date of issuance. The warrants are exercisable in whole or in part and contain a cashless exercise provision.
Preferred Stock Voting and Other Rights
Generally, the Company's Preferred Stock votes together on an as converted basis with the holders of Common Stock. In addition, the Company's Preferred Stock enjoys certain protective provisions, a liquidation preference and anti-dilution protection that are similar to one another.
Warrants
A summary of the warrant activity is as follows:
	31-Mar-14		31-Dec-13
	Warrants	Weighted	Warrants	Weighted
		Average		Average
		Exercise Price		Exercise Price
Outstanding at beginning of period	77,155	$	151,722	$
		0.0289		0.0269
Issued	21,418	$	-	$
		0.0275		-
Exercised	-	$	-1,300	$
		-		0.028
Expired	-4,333	$	-1,400	$
		0.0225		0.0225
Outstanding at end of period	94,240	$	149,022	$
		0.0289		0.0257
Exercisable at end of period	94,240	$	149,022	$
		0.0289		0.0257
A summary of the status of the warrants outstanding and exercisable as of March 31, 2014, is as follows:
Number of Warrants	Weighted Average	Weighted Average
	Remaining Life	Exercise Price per
		share
13,069	0.71	$
		0.0225
72,528	2.77	$
		0.0275
8,643	1.31	$
		0.05
94,240	2.35	$
		0.0289
Contingent warrants
Investors that received warrants in connection with the December 13, 2013 and February 7 and March 6, 2014, offerings may receive warrants to purchase up to 89,421 additional shares of Common Stock, if the Company does not achieve certain revenue targets in the first three quarters of 2014. The Company ascribed a value of $566 to the warrants issued at closing, including the contingent warrants, using a Black Sholes valuation model. The Company also recorded a beneficial conversion feature related to the shares of Series D Preferred Stock issued in the February 7 and March 6, 2014 financings, of $305 based on the accounting conversion price of the shares of Series D Preferred Stock issued. Since the Company did not achieve the revenue target for the three month period ended March 31, 2014, the Company will issue warrants to purchase 29,952 shares of common stock promptly after filing of this Form 10-Q.
At March 31, 2014, 94,240 shares of common stock were reserved for issuance upon exercise of outstanding warrants.

Subsequent_event

Subsequent event	3 Months Ended
	Mar. 31, 2014
Subsequent Event [Abstract]	'
Subsequent event	'
	7. Subsequent event
	On May 6, 2014, the Company entered into a Credit Agreement with Venture Champion Asia Limited, an affiliate of ICG Global Limited (the "Lender"). Under the terms of the Credit Agreement, for a period of 18 months, the Company is permitted to borrow up to $2 million in unsecured indebtedness from the Lender. Each draw is subject to a 15% original issue discount, so that borrowing the full $2 million would result in an aggregate of $2.352 million in debt with fifty percent (50%) warrant coverage and also may be converted at the Lender's option into shares of the Company's Common Stock at a conversion price of $0.0275 per share.
	In connection with the Company's entry into the Credit Agreement, the Company issued the Lender a warrant to purchase approximately 10,909 shares of Common Stock.

Nature_of_business_basis_of_pr1

Nature of business, basis of presentation and summary of significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies	'
Basis of presentation	'
	The accompanying unaudited condensed consolidated financial statements of Communication Intelligence Corporation and its subsidiary (the "Company" or "CIC") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year.
Going concern and management plans	'
	The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Except for 2004, the Company has incurred significant losses since its inception and, at March 31, 2014, the Company's accumulated deficit was approximately $120,245. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2014, the Company's cash balance was approximately $1,147. These factors raise substantial doubt about the Company's ability to continue as a going concern.
	There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Reclassifications	'Reclassifications
	Certain prior year amounts have been reclassified between Series C Preferred Stock, Series D-1 Preferred Stock, Series D-2 Preferred Stock and Additional paid in capital on the accompanying condensed consolidated balance sheet to properly reflect accretion of the beneficial conversion feature on certain issuances of the Company's Preferred Stock. These reclassifications do not impact the condensed consolidated statement of operations or the condensed consolidated statement of cash flows.
Recently issued accounting pronouncement	'
	Accounting Standards Issued But Not Yet Adopted
	Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company's financial position, results of operations and cash flows.
Patents	'
	The Company performs intangible asset impairment analysis at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets.
Derivatives policy	'
	The Company has determined that a contract that would otherwise meet the definition of a derivative but is both (a) indexed to the Company's own stock and (b) classified in stockholders' equity in the statement of financial position would not be considered a derivative financial instrument. The Company applies a two-step model in determining whether a financial instrument or an embedded feature is indexed to an issuer's own stock and thus able to qualify for the scope exception.
Fair Value of Financial Instruments	'
	The Company issued certain warrants in connection with financing transactions from 2010 through 2012 that require liability classification because of certain provisions that may have resulted in an adjustment to the number of shares issued upon settlement and an adjustment to their exercise price. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company used a simulated probability valuation model to value these warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically, probabilities) used may cause the value to be higher or lower than that reported. The assumptions used in the model required significant judgment by management and include the following: volatility, expected term, risk-free interest rate, dividends, warrant holders' expected rate of return, reset provisions based on expected future financings, projected stock prices, and probability of exercise. The estimated volatility of the Company's common stock at the date of issuance, and at each subsequent reporting period, is based on historical volatility. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Dividends are estimated at 0% based on the Company's history of no common stock dividends.
Fair value measurement	'
	The fair value framework requires a categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets and liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:
	Level 1: Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
	Level 2: Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
	Level 3: Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
Net loss per share	'
	The Company calculates basic net loss per share, based on the weighted average number of shares outstanding, and when applicable, diluted income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding.
Share-based payment	'
	Share-based compensation expense is based on the estimated grant date fair value of the portion of share-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black Scholes valuation model.
	Forfeitures of share-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Concentration_Tables

Concentration (Tables)	3 Months Ended
	Mar. 31, 2014
Risks and Uncertainties [Abstract]	'
Schedule of accounts receivable and revenue concentration	'
	The following table summarizes accounts receivable and revenue concentrations:
		Accounts Receivable		Total Revenue
		As of March 31,		for the three months
				ended March 31,
		2014	2013	2014	2013
	Customer #1	32%	37%	12%
	Customer #2	26%
	Customer #3	18%		22%
	Customer #4		18%
	Customer #5		18%
	Customer #6			12%	15%
	Customer #7				15%
	Total concentration	76%	73%	46%	30%

Patents_Tables

Patents (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Summary of Intangible Assets	'
	The following table summarizes intangible assets:
	Amortizable intangible assets:	31-Mar-14		31-Dec-13
		Carrying	Accumulated	Carrying	Accumulated
		Amount	Amortization	Amount	Amortization
	Patents	$	$	$	$
		6,745	-5,544	6,745	-5,455

Derivative_Liability_Tables

Derivative Liability (Tables)	3 Months Ended
	Mar. 31, 2014
Derivative liability [Abstract]	'
Liabilities measured at fair value	'
	Assets and liabilities measured at fair value as of March 31, 2014, are as follows:
		Value at	Quoted	Significant	Significant
			prices in	other	unobservable
			active	observable	inputs
			markets	inputs
			(Level 1)	(Level 2)	(Level 3)
		31-Mar-14
	Derivative liability	$	$	$	$
		20	-	-	20
		31-Dec-13
	Derivative liability	$	$	$	$
		25	-	-	25
Changes in the market value of the Level 3 derivative liability	'
	Changes in the fair market value of the Level 3 derivative liability for the three month period ended March 31, 2014 are as follows:
		Derivative Liability
	Balance at January 1, 2014	$
		25
	Gain on derivative liability	-5
	Balance at March 31, 2014	$
		20

Net_loss_per_share_Tables

Net loss per share (Tables)	3 Months Ended
	Mar. 31, 2014
Net loss per share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Calculation of Earnings Per Share	'
	The following table lists shares and warrants that were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants and the conversion of such preferred shares would be anti-dilutive:
		For the three Months Ended
		31-Mar-14	31-Mar-13
	Stock options	72,038	70,270
	Warrants	94,240	149,022
	Preferred shares as if converted
	Series A-1Preferred Stock	7,513	6,941
	Series B Preferred Stock	17,065	237,866
	Series C Preferred Stock	205,294	190,146
	Series D-1 Preferred Stock	191,189	51,193
	Series D-2 Preferred Stock	106,069	67,682
Reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted EPS calculations	'
	The following table is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted EPS calculations and sets forth potential shares of Common Stock that are not included in the diluted net loss per share calculation as the effect is antidilutive:
		Three Months Ended
		March 31,	March 31,
		2014	2013
	Numerator-basic and diluted net loss	$	$
		-2,056	-1,730
	Denominator-basic or diluted weighted average number of common shares outstanding	232,560	225,875
	Net loss per share - basic and diluted	$	$
		-0.01	-0.01

Equity_Tables

Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Key assumptions for fair value calculation, stock options	'
	The fair value calculations are based on the following assumptions:
		Three Months Ended	Three Months Ended
		31-Mar-14	31-Mar-13
	Risk free interest rate	0.04% - 4.92%	0.62% - 5.11%
	Expected term (years)	3.33 - 6.21	2.82 - 7.00
	Expected volatility	91.99% - 198.38%	93.63% - 147.41%
	Expected dividends	None	None
Allocation of stock-based compensation expense related to stock option grants	'
	The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three months ended March 31:
		2014	2013
	Research and development	$	$
		27	68
	Sales and marketing	12	25
	General and administrative	48	146
	Director	5	15
	Total Stock-based compensation	$	$
		92	254
Summary of option activity	'
	A summary of option activity under the Company's plans as of March 31, 2014 and 2013 is as follows:
	Options	2014				2013
		Shares	Weighted	Weighted	Aggregate	Shares	Weighted	Weighted	Aggregate
			Average	Average	Intrinsic		Average	Average	Intrinsic
			Exercise	Remaining	Value		Exercise	Remaining	Value
			Price	Contractual			Price	Contractual
				Term				Term
	Outstanding at January 1,	69,537	$		$	44,529	$		$
			0.05		-		0.05		2,230
	Granted	2,500	$		$	26,241	$		$
			0.03		7		0.04		1,179
	Exercised	-	$		$	-	$		$
			-		-		-		-
	Forfeited or expired	-	$		$	-500	$		$
			-		-		0.09		43
	Outstanding at March 31	72,037	$	4.85	$	70,270	$	5.75	$
			0.05		7		0.05		3,367
	Vested and expected to vest at March 31	65,007	$	4.41	$	70,270	$	5.05	$
			0.05		7		0.05		3,367
	Exercisable at March 31	48,445	$	5.05	$	27,036	$	5.05	$
			0.05		-		0.05		1,043
Summary of the significant ranges of outstanding and exercisable options	'
	The following tables summarize significant ranges of outstanding and exercisable options as of March 31, 2014:
	Range of Exercise Prices	Options Outstanding			Options Exercisable
		Number	Weighted	Weighted	Number	Weighted
		Outstanding	Average	Average	Outstanding	Average
			Remaining	Exercise		Exercise
			Contractual	Price		Price
			Term (in years)
	$ 0.07 - $0.50	72,037	4.85	$	48,445	$
				0.05		0.05
Summary of the status of the Company's non-vested shares	'
	A summary of the status of the Company's non-vested shares as of March 31, 2014, is as follows:
	Non-vested Shares	Shares	Weighted
			Average
			Grant-Date
			Fair Value
	Non-vested at January 1, 2014	26,158	$
			0.04
	Granted	2,500	$
			0.03
	Exercised	-	$
			-
	Forfeited	-	$
			-
	Vested	-5,066	$
			0.04
	Non-vested at March 31, 2014	23,592	$
			0.04
Information with respect to the classes of Preferred Stock	'
	Information with respect to the class of Preferred Stock as of March 31, 2014 is as follows:
	Class of	Issue Date	Annual	Annual	Liquidation	Conversion	Total	Common
	Preferred		Dividend	Dividend	Preference	Price	Preferred	Shares to be
	Stock			Payable, in			Shares	issued if
				Cash or In			Outstanding	Fully
				Kind				Converted
	Series A-1	May-08	8%	Quarterly in Arrears	$	$	1,052	7,514
					1	0.14
	Series B	Aug-10	10%	Quarterly in Arrears	$	$	11,377	262,559
					1.5	0.0433
	Series C	December/March 2011	10%	Quarterly in Arrears	$	$	4,619	205,294
					1.5	0.0225
	Series D-1	November 2012/May and December 2013/February and March 2014	10%	Quarterly in Arrears	$	$	4,302	191,189
					1	0.0225
	Series D-2	November 2012/May and December 2013/February and March 2014	10%	Quarterly in Arrears	$	$	5,303	106,068
					1	0.05
Information with respect to dividends issued on the Company's preferred stock	'
	Information with respect to dividends issued on the Company's Preferred stock for the period ended March 31, is as follows:
		March 31,		March 31,
		2014	2013	2014	2013
		Dividends		Beneficial Conversion Feature
				Related to dividends
	Series A-1	$	$	$	$
		20	19	-	-
	Series B	274	248	-	-
	Series C	111	103	37	43
	Series D-1	93	28	31	12
	Series D-2	123	81	-	-
	Total	$	$	$	$
		621	478	68	55
Summary of the warrants issued	'
	A summary of the warrant activity is as follows:
		31-Mar-14		31-Dec-13
		Warrants	Weighted	Warrants	Weighted
			Average		Average
			Exercise Price		Exercise Price
	Outstanding at beginning of period	77,155	$	151,722	$
			0.0289		0.0269
	Issued	21,418	$	-	$
			0.0275		-
	Exercised	-	$	-1,300	$
			-		0.028
	Expired	-4,333	$	-1,400	$
			0.0225		0.0225
	Outstanding at end of period	94,240	$	149,022	$
			0.0289		0.0257
	Exercisable at end of period	94,240	$	149,022	$
			0.0289		0.0257
Status of the warrants outstanding	'
	A summary of the status of the warrants outstanding and exercisable as of March 31, 2014, is as follows:
	Number of Warrants	Weighted Average	Weighted Average
		Remaining Life	Exercise Price per
			share
	13,069	0.71	$
			0.0225
	72,528	2.77	$
			0.0275
	8,643	1.31	$
			0.05
	94,240	2.35	$
			0.0289

Nature_of_business_basis_of_pr2

Nature of business, basis of presentation and summary of significant accounting policies (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	$1,147	$945	$197	$486
Accumulated deficit	($120,245)	($119,184)	'	'

Concentrations_Details

Concentrations (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Accounts Receivable [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	76.00%	73.00%
Accounts Receivable [Member] | Customer One [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	32.00%	37.00%
Accounts Receivable [Member] | Customer Two[Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	26.00%	'
Accounts Receivable [Member] | Customer Three [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	18.00%	'
Accounts Receivable [Member] | Customer Four [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	'	18.00%
Accounts Receivable [Member] | Customer Five [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	'	18.00%
Sales Revenue, Services, Net [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	46.00%	30.00%
Sales Revenue, Services, Net [Member] | Customer One [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	12.00%	'
Sales Revenue, Services, Net [Member] | Customer Three [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	22.00%	'
Sales Revenue, Services, Net [Member] | Customer Six [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	12.00%	15.00%
Sales Revenue, Services, Net [Member] | Customer Seven [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk, percentage	'	15.00%

Patents_Details

Patents (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Amortizable intangible assets	'	'
Finite-lived intangible assets, gross	$6,745	$6,745
Finite-Lived intangible assets, accumulated amortization	($5,544)	($5,455)

Patents_Details_Textual

Patents (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Patent amortization expense	$89	$92
Patents impairment	$0	$0

Derivative_liability_Details

Derivative liability (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Liabilities measured at fair value	'	'
Derivative liability	$20	$25
Fair Value, Inputs, Level 1 [Member]	'	'
Liabilities measured at fair value	'	'
Derivative liability	'	'
Fair Value, Inputs, Level 2 [Member]	'	'
Liabilities measured at fair value	'	'
Derivative liability	'	'
Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities measured at fair value	'	'
Derivative liability	$20	$25

Derivative_liability_Details_1

Derivative liability (Details 1) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Balance at beginning of period	$25
Gain on derivative liability	-5
Balance at end of period	$20

Derivative_Liability_Details_T

Derivative Liability (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Derivative Liability, Fair Value, Net [Abstract]	'	'
Fair value of the derivative liability	$20	$25
Annual Dividend	0.00%	'

Net_loss_per_share_Details

Net loss per share (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Series A Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	7,513	6,941
Series B Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	17,065	237,866
Series C Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	205,294	190,146
Series D One Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	191,189	51,193
Series D Two Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	106,069	67,682
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	72,038	70,270
Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	94,240	149,022

Net_loss_per_share_Details_1

Net loss per share (Details 1) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share Reconciliation [Abstract]	'	'
Numerator - basic and diluted net loss	($2,056)	($1,730)
Weighted average common shares outstanding, basic and diluted	232,560	225,875
Net loss per share - bacis and diluted	($0.01)	($0.01)

Equity_Details

Equity (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]	'	'
Risk-free interest rate, minimum	0.04%	0.62%
Risk-free interest rate, maximum	4.92%	5.11%
Expected volatility, minimum	91.99%	93.63%
Expected volatility, maximum	198.38%	147.41%
Expected dividend yield	$0	$0
Minimum [Member]	'	'
Fair value assumptions, stock options	'	'
Expected life	'3 years 3 months 2 days	'2 years 10 months 6 days
Maximum [Member]	'	'
Fair value assumptions, stock options	'	'
Expected life	'6 years 10 months 17 days	'7 years

Equity_Details_1

Equity (Details 1) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$90	$254
Research and Development Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	27	68
Selling and Marketing Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	12	25
General and Administrative Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	48	146
Director Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$5	$15

Equity_Details_2

Equity (Details 2) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Summary of stock options outstanding	'	'	'
Stock Options Outstanding, Beginning Balance	69,537	44,529	'
Stock Options, Granted	2,500	26,241	'
Stock Options, Exercised	0	0	'
Stock Options, Forfeited, or expired	'	-500	'
Stock Options Outstanding, Ending Balance	72,037	70,270	'
Stock Options, Vested and expected to vest at ending balance	65,007	70,270	'
Options exercisable	48,445	27,036	'
Weighted Average Exercise Price, Beginning Period	$0.05	'	'
Weighted Average Exercise Price, Granted	$0.03	$0.04	'
Weighted Average Exercise Price, Exercised	'	'	'
Weighted Average Exercise Price, Forfeited, or expired	'	$0.09	'
Weighted Average Exercise Price, Ending Period	$0.05	$0.05	'
Weighted Average Exercise Price, Vested and expected to vest at ending balance	$0.05	$0.05	'
Weighted Average Exercise Price, Exercisable at ending balance	$0.05	$0.05	$0.05
Weighted Average Remaining Contractual Term, ending balance	'7 years 10 months 1 day	'5 years 9 months	'
Weighted Average Remaining Contractual Term, vested and expected to vest at ending balance	'4 years 10 months 1 day	'5 years 0 months 2 days	'
Weighted Average Remaining Contractual Term, excercisable at ending balance	'5 years 0 months 2 days	'5 years 0 months 2 days	'
Aggregate Intrinsic Value, Beginning Balance	'	$2,230	'
Aggregate Intrinsic Value, Granted	7	1,179	'
Aggregate Intrinsic Value, Exercised	'	'	'
Aggregate Intrinsic Value, Forfeited or expired	'	43	'
Aggregate Intrinsic Value, Ending Balance	7	3,367	'
Aggregate Intrinsic Value, Vested and expected to vest at ending balance	7	3,367	'
Aggregate Intrinsic Value, Exercisable at ending balance	'	$1,043	'

Equity_Details_3

Equity (Details 3) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
In Thousands, except Per Share data, unless otherwise specified			Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price Range, Lower Range Limit	'	'	$0.07
Exercise Price Range, Upper Range Limit	'	'	$0.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]	'	'	'
Number of Outstanding Options	'	'	72,037
Outstanding Options, Weighted Average Remaining Contractual Term	'	'	'4 years 10 months 1 day
Outstanding Options, Weighted Average Exercise Price	$0.03	$0.04	$0.05
Exercise Price Range, Number of Exercisable Options	'	'	48,445
Exercisable Options, Weighted Average Exercise Price	'	'	$0.05

Equity_Details_4

Equity (Details 4) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Equity Instruments, Options, Nonvested Shares Roll-Forward	'
Non-vested shares, Beginning Balance	26,158
Non-vested shares, Granted	2,500
Non-vested shares, Forfeited, or expired	'
Non-vested shares, vested	-5,066
Stock Options Outstanding, Ending Balance	23,592
Weighted Average Grant Date Fair Value, Options Nonvested at beginning of period	$0.04
Weighted Average Grant Date Fair Value, Options nonvested, grants in period	$0.03
Weighted Average Grant Date Fair Value, Options nonvested, forfeited in period	'
Weighted Average Grant Date Fair Value, Options nonvested, vested in period	$0.04
Weighted Average Grant Date Fair Value, Options nonvested at end of period	$0.04

Equity_Details_5

Equity (Details 5) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Annual Dividend	0.00%	'
Common Shares to be Issued if Fully Converted	772,624,000	'
Series A Preferred Stock [Member]	'	'
Issue Date	'May 2008	'
Annual Dividend	8.00%	'
Annual Dividend Payable, in Cash or In Kind	'Quarterly in Arrears	'
Liquidation preference	$1	'
Conversion price	$0.14	'
Total Preferred Shares Outstanding	1,052,000	1,031,000
Common Shares to be Issued if Fully Converted	7,514,000	'
Series B Preferred Stock [Member]	'	'
Issue Date	'August 2010	'
Annual Dividend	10.00%	'
Annual Dividend Payable, in Cash or In Kind	'Quarterly in Arrears	'
Liquidation preference	1.5	'
Conversion price	$0.04	'
Total Preferred Shares Outstanding	11,377,000	11,102,000
Common Shares to be Issued if Fully Converted	262,559,000	'
Series C Preferred Stock [Member]	'	'
Issue Date	'December / March 2011	'
Annual Dividend	10.00%	'
Annual Dividend Payable, in Cash or In Kind	'Quarterly in Arrears	'
Liquidation preference	1.5	'
Conversion price	$0.02	'
Total Preferred Shares Outstanding	4,619,000	4,508,000
Common Shares to be Issued if Fully Converted	205,294,000	'
Series D One Preferred Stock [Member]	'	'
Issue Date	'November 2012 / May and December 2013 / February and March 2014	'
Annual Dividend	10.00%	'
Annual Dividend Payable, in Cash or In Kind	'Quarterly in Arrears	'
Liquidation preference	1	'
Conversion price	$0.02	'
Total Preferred Shares Outstanding	4,302,000	3,415,000
Common Shares to be Issued if Fully Converted	191,189,000	'
Series D Two Preferred Stock [Member]	'	'
Issue Date	'November 2012 / May and December 2013 / February and March 2014	'
Annual Dividend	10.00%	'
Annual Dividend Payable, in Cash or In Kind	'Quarterly in Arrears	'
Liquidation preference	$1	'
Conversion price	$0.05	'
Total Preferred Shares Outstanding	5,303,000	4,783,000
Common Shares to be Issued if Fully Converted	106,068,000	'

Equity_Details_6

Equity (Details 6) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Dividends Net of Beneficial Conversion Feature	$621	$478
Accretion of beneficial conversion feature related to dividends	68	55
Series A Preferred Stock [Member]	'	'
Dividends Net of Beneficial Conversion Feature	20	19
Accretion of beneficial conversion feature related to dividends	'	'
Series B Preferred Stock [Member]	'	'
Dividends Net of Beneficial Conversion Feature	274	248
Accretion of beneficial conversion feature related to dividends	'	'
Series C Preferred Stock [Member]	'	'
Dividends Net of Beneficial Conversion Feature	111	103
Accretion of beneficial conversion feature related to dividends	37	43
Series D One Preferred Stock [Member]	'	'
Dividends Net of Beneficial Conversion Feature	93	28
Accretion of beneficial conversion feature related to dividends	31	12
Series D Two Preferred Stock [Member]	'	'
Dividends Net of Beneficial Conversion Feature	123	81
Accretion of beneficial conversion feature related to dividends	'	'

Equity_Details_7

Equity (Details 7) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Class Of Warrant Or Right Number Of Warrants Or Rights Roll Forward	'	'
Number of Warrants Outstanding at beginning of period	77,155	151,722
Number of warrants issued	21,418	'
Number Of Warrants Or Rights Exercised	'	-1,300
Number Of Warrants Or Rights Expired	-4,333	-1,400
Number of Warrants Outstanding at end of period	94,240	149,022
Number of Warrants Or Rights Exercisable at end of period	94,240	149,022
Excercise Price of Warrants Outstanding at beginning of period	$0.03	$0.03
Exercise Price Of Warrants Issued	$0.03	'
Exercise Price Of Warrants Exercised	'	$0.03
Exercise Price Of Warrants Expired	$0.02	$0.02
Excercise Price of Warrants Outstanding at end of period	$0.03	$0.03
Exercise Price Of WarrantsExercisable at end of period	$0.03	$0.03

Equity_Details_8

Equity (Details 8) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]	'	'	'	'
Number of Warrants Outstanding and Excercisable	94,240	77,155	149,022	151,722
Weighted Average Remaining Life Of Warrants Or Rights	'2 years 4 months 17 days	'	'	'
Warrants Weighted Average Exercise Price	$0.03	$0.03	$0.03	$0.03
Warrants Group One [Member]	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'
Number of Warrants Outstanding and Excercisable	13,069	'	'	'
Weighted Average Remaining Life Of Warrants Or Rights	'8 months 16 days	'	'	'
Warrants Weighted Average Exercise Price	$0.02	'	'	'
Warrants Group Two [Member]	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'
Number of Warrants Outstanding and Excercisable	72,528	'	'	'
Weighted Average Remaining Life Of Warrants Or Rights	'2 years 9 months 7 days	'	'	'
Warrants Weighted Average Exercise Price	$0.03	'	'	'
Warrants Group Three [Member]	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'
Number of Warrants Outstanding and Excercisable	8,643	'	'	'
Weighted Average Remaining Life Of Warrants Or Rights	'1 year 3 months 22 days	'	'	'
Warrants Weighted Average Exercise Price	$0.05	'	'	'

Equity_Details_Textual

Equity (Details Textual) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-based Arrangements with Employees and Nonemployees [Abstract]	'	'
Estimated average forfeiture rate	9.76%	9.73%
Stock Options, Granted	2,500	26,241
Outstanding Options, Weighted Average Exercise Price	$0.03	$0.04
Stock Options, Exercised	0	0
Total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans	$292	'
Unrecognized compensation expense amortization period	'1 year 1 month 6 days	'

Equity_Details_Textual_1

Equity (Details Textual 1) (USD $)

3 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

In Thousands, except Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Feb. 28, 2014

Dec. 31, 2013

31-May-13

Mar. 31, 2014

Feb. 28, 2014

Dec. 31, 2013

31-May-13

Feb. 07, 2014

Mar. 31, 2014

Feb. 28, 2014

Dec. 31, 2013

31-May-13

Feb. 07, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Nov. 30, 2012

Warrants Issued to SG Phoenix [Member]

Warrants Issued to SG Phoenix [Member]

Warrants Issued to Unrelated Parties [Member]

Warrants Issued to Unrelated Parties [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D One Preferred Stock [Member]

Series D One Preferred Stock [Member]

Series D One Preferred Stock [Member]

Series D One Preferred Stock [Member]

Series D One Preferred Stock [Member]

Series D Two Preferred Stock [Member]

Series D Two Preferred Stock [Member]

Series D Two Preferred Stock [Member]

Series D Two Preferred Stock [Member]

Series D Two Preferred Stock [Member]

Series D Two Preferred Stock For Cash [Member]

February And March Two Thousand Fourteen Note And Warrant Purchase Agreement [Member]

February And March Two Thousand Fourteen Note And Warrant Purchase Agreement [Member]

Series D Financing [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Contingent Warrants [Member]

Contingent Warrants [Member]

Subsequent Event [Member]

Subsidiary, Sale of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Units, Issued

'

'

'

'

'

'

'

'

'

230,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Units, Components

'

'

'

'

'

'

'

'

'

'

'

'

'

1

2

'

'

'

4

1

'

'

'

'

Preferred Units, Description

'

'

'

'

'

'

'

'

'

'Units of Series D Preferred Shares consisting of one (1) share of Series D-1 Preferred Stock with an exercise price of $0.0025 per share and four (4) shares of Series D-2 Preferred Stock at an exercise price of $0.05 per share.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from sale of stock, net

'

'

'

'

'

'

$406

$733

$870

$1,150

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Administrative fee paid to SG Phoenix

'

'

'

'

'

'

4

47

40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares sold in private placement

'

'

'

'

'

'

'

'

'

'

273,000

520,000

607,000

'

'

137,000

260,000

303,000

'

'

'

'

'

'

Conversion of short-term debt and accrued interest, net of offering costs

'

'

'

'

'

'

'

'

1,179

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,099

Shares issued in debt conversion

'

'

'

'

'

'

'

'

'

'

'

'

786,000

'

'

'

'

393,000

'

'

'

'

'

'

Warrant coverage, maximum percentage

'

'

'

'

'

'

100.00%

100.00%

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Term

'

'

'3 years

'

'3 years

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of Series D-2 Preferred Stock exchanged into Series D-1 Preferred Stock

'

'

'

'

'

'

'

'

537,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, expiration date

'

'

'

'

'

'

31-Dec-16

31-Dec-16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common shares callable by warrants

'

'

'

3,000,000

'

1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

89,421,000

29,952,000

'

Number of common shares, reserved for issuance upon exercise of outstanding warrants

94,240,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price per share for the shares sold in private placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

Fair value of contingent warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

566

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature

$306

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$305

'

'

Subsequent_Event_Details_Textu

Subsequent Event (Details Textual) (Subsequent Event [Member], Venture Champion Asia Limited [Member], USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Subsequent Event [Line Items]	'
Subsequent Event, Date	6-May-14
Subsequent Event, Description	'Credit Agreement
Line of Credit Facility, Current Borrowing Capacity	$2,000
Line of Credit Facility, Maximum Borrowing Capacity	$2,352
Line of Credit Facility, Expiration Period	'18 months
Conversion price	$0.03
Original issue discount, percentage	15.00%
Warrant coverage, maximum percentage	50.00%
Credit Agreement Warrant [Member]	'
Subsequent Event [Line Items]	'
Number of common shares callable by warrants	10,909